| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 25 | 2021 | 1180 | 3.450 |
Why?
|
| Stroke Volume | 13 | 2021 | 462 | 2.930 |
Why?
|
| Coronary Circulation | 5 | 2024 | 131 | 2.310 |
Why?
|
| Pulmonary Embolism | 4 | 2021 | 228 | 1.700 |
Why?
|
| Cardiac Catheterization | 10 | 2019 | 302 | 1.680 |
Why?
|
| Ventricular Function, Left | 9 | 2021 | 603 | 1.600 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2018 | 329 | 1.460 |
Why?
|
| Coronary Artery Disease | 9 | 2024 | 362 | 1.460 |
Why?
|
| Microcirculation | 4 | 2024 | 104 | 1.460 |
Why?
|
| Aortic Valve Stenosis | 5 | 2020 | 143 | 1.400 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2020 | 51 | 1.370 |
Why?
|
| Microvessels | 2 | 2019 | 69 | 1.260 |
Why?
|
| Vascular Calcification | 2 | 2019 | 51 | 1.210 |
Why?
|
| Coronary Vessels | 4 | 2024 | 190 | 1.160 |
Why?
|
| Thrombolytic Therapy | 3 | 2018 | 232 | 1.090 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2019 | 64 | 1.000 |
Why?
|
| Benzazepines | 6 | 2012 | 64 | 0.970 |
Why?
|
| Radial Artery | 4 | 2019 | 33 | 0.920 |
Why?
|
| Hospitalization | 7 | 2015 | 876 | 0.920 |
Why?
|
| Renal Insufficiency | 3 | 2015 | 98 | 0.870 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2019 | 66 | 0.800 |
Why?
|
| Heart-Assist Devices | 5 | 2021 | 756 | 0.730 |
Why?
|
| Heart Diseases | 2 | 2016 | 298 | 0.730 |
Why?
|
| Coronary Artery Bypass | 3 | 2019 | 234 | 0.710 |
Why?
|
| Heart Arrest | 3 | 2018 | 279 | 0.700 |
Why?
|
| Electrocardiography | 2 | 2019 | 493 | 0.680 |
Why?
|
| Ventricular Pressure | 3 | 2021 | 37 | 0.670 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2019 | 12 | 0.670 |
Why?
|
| Hemodynamics | 5 | 2024 | 729 | 0.670 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2019 | 99 | 0.670 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 7 | 0.660 |
Why?
|
| Catheterization, Peripheral | 1 | 2019 | 60 | 0.660 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 63 | 0.650 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 250 | 0.640 |
Why?
|
| Atherectomy, Coronary | 1 | 2018 | 2 | 0.640 |
Why?
|
| Cardiac Catheters | 1 | 2018 | 12 | 0.640 |
Why?
|
| Treatment Outcome | 21 | 2024 | 8203 | 0.630 |
Why?
|
| Patient Readmission | 4 | 2017 | 351 | 0.630 |
Why?
|
| Aged | 33 | 2024 | 19077 | 0.610 |
Why?
|
| Humans | 68 | 2024 | 89063 | 0.600 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 4 | 2012 | 27 | 0.590 |
Why?
|
| Triage | 1 | 2018 | 111 | 0.580 |
Why?
|
| Echocardiography | 5 | 2018 | 937 | 0.580 |
Why?
|
| Myocardium | 3 | 2018 | 571 | 0.560 |
Why?
|
| Etiocholanolone | 4 | 2009 | 5 | 0.560 |
Why?
|
| Cardio-Renal Syndrome | 2 | 2019 | 6 | 0.560 |
Why?
|
| Device Removal | 1 | 2018 | 167 | 0.560 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 167 | 0.550 |
Why?
|
| Female | 45 | 2024 | 46011 | 0.550 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 214 | 0.530 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2275 | 0.530 |
Why?
|
| Male | 42 | 2024 | 42251 | 0.520 |
Why?
|
| Retrospective Studies | 16 | 2021 | 9003 | 0.520 |
Why?
|
| Middle Aged | 37 | 2024 | 25863 | 0.520 |
Why?
|
| Endoscopy | 1 | 2019 | 348 | 0.510 |
Why?
|
| Point-of-Care Systems | 4 | 2008 | 148 | 0.500 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 6777 | 0.490 |
Why?
|
| Creatinine | 1 | 2015 | 293 | 0.490 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 264 | 0.480 |
Why?
|
| Kidney | 2 | 2019 | 1145 | 0.470 |
Why?
|
| Coronary Angiography | 7 | 2023 | 242 | 0.450 |
Why?
|
| Cardiotonic Agents | 3 | 2009 | 89 | 0.450 |
Why?
|
| Thrombosis | 1 | 2016 | 302 | 0.440 |
Why?
|
| Neurotransmitter Agents | 2 | 2019 | 108 | 0.430 |
Why?
|
| Ischemia | 3 | 2020 | 251 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2657 | 0.420 |
Why?
|
| Risk Factors | 7 | 2021 | 5466 | 0.390 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 161 | 0.360 |
Why?
|
| Popliteal Artery | 2 | 2020 | 28 | 0.360 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 1715 | 0.350 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1114 | 0.350 |
Why?
|
| Absorbable Implants | 2 | 2020 | 34 | 0.350 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2019 | 181 | 0.340 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 96 | 0.340 |
Why?
|
| Shock, Cardiogenic | 2 | 2024 | 106 | 0.340 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 94 | 0.320 |
Why?
|
| Vascular Resistance | 2 | 2019 | 101 | 0.320 |
Why?
|
| Vasopressins | 1 | 2008 | 50 | 0.320 |
Why?
|
| Prognosis | 9 | 2019 | 3773 | 0.320 |
Why?
|
| Weight Gain | 1 | 2009 | 119 | 0.310 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 188 | 0.300 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2019 | 346 | 0.300 |
Why?
|
| Amyloidosis | 1 | 2009 | 127 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 859 | 0.290 |
Why?
|
| Biomarkers | 6 | 2019 | 1755 | 0.290 |
Why?
|
| Angina Pectoris | 2 | 2023 | 28 | 0.280 |
Why?
|
| Spironolactone | 2 | 2021 | 12 | 0.280 |
Why?
|
| Pulmonary Wedge Pressure | 5 | 2021 | 113 | 0.270 |
Why?
|
| Hospital Mortality | 2 | 2021 | 386 | 0.270 |
Why?
|
| Cardiovascular Agents | 3 | 2012 | 54 | 0.270 |
Why?
|
| Heart | 4 | 2019 | 573 | 0.260 |
Why?
|
| Causality | 2 | 2017 | 80 | 0.250 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2019 | 223 | 0.250 |
Why?
|
| Prospective Studies | 7 | 2019 | 4273 | 0.250 |
Why?
|
| Double-Blind Method | 6 | 2012 | 1714 | 0.240 |
Why?
|
| Echocardiography, Three-Dimensional | 3 | 2019 | 516 | 0.240 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 3 | 2009 | 79 | 0.240 |
Why?
|
| Myocardial Bridging | 1 | 2023 | 5 | 0.230 |
Why?
|
| Time Factors | 6 | 2020 | 5320 | 0.230 |
Why?
|
| Exercise Test | 1 | 2024 | 165 | 0.220 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 82 | 0.220 |
Why?
|
| Blood Pressure | 4 | 2008 | 899 | 0.220 |
Why?
|
| Vena Cava, Inferior | 4 | 2008 | 145 | 0.210 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2021 | 17 | 0.210 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 113 | 0.210 |
Why?
|
| Myocardial Revascularization | 2 | 2014 | 30 | 0.200 |
Why?
|
| Heart Atria | 3 | 2016 | 281 | 0.200 |
Why?
|
| Comorbidity | 2 | 2017 | 948 | 0.190 |
Why?
|
| Catheters | 1 | 2021 | 76 | 0.190 |
Why?
|
| Lower Extremity | 1 | 2021 | 87 | 0.190 |
Why?
|
| Equipment Failure | 2 | 2018 | 121 | 0.180 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2020 | 5 | 0.180 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2752 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2020 | 2290 | 0.180 |
Why?
|
| Equipment Design | 3 | 2018 | 415 | 0.180 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1837 | 0.180 |
Why?
|
| Punctures | 1 | 2019 | 29 | 0.170 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2019 | 4 | 0.170 |
Why?
|
| Fibrosis | 2 | 2020 | 234 | 0.170 |
Why?
|
| Survival Rate | 3 | 2020 | 1889 | 0.170 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 105 | 0.170 |
Why?
|
| Mitral Valve | 2 | 2018 | 262 | 0.170 |
Why?
|
| Sutureless Surgical Procedures | 1 | 2019 | 6 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 738 | 0.170 |
Why?
|
| Septal Occluder Device | 1 | 2019 | 44 | 0.170 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2019 | 69 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2009 | 51 | 0.160 |
Why?
|
| Illinois | 2 | 2018 | 472 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2019 | 948 | 0.160 |
Why?
|
| United States | 5 | 2019 | 6955 | 0.160 |
Why?
|
| Radiation Dosage | 1 | 2019 | 225 | 0.160 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3657 | 0.160 |
Why?
|
| Drug-Eluting Stents | 1 | 2018 | 16 | 0.160 |
Why?
|
| Hospitals | 1 | 2021 | 299 | 0.160 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2018 | 23 | 0.160 |
Why?
|
| rho-Associated Kinases | 1 | 2020 | 160 | 0.160 |
Why?
|
| Fatal Outcome | 1 | 2019 | 299 | 0.160 |
Why?
|
| Disease Progression | 2 | 2015 | 1488 | 0.160 |
Why?
|
| Hospital Costs | 1 | 2019 | 107 | 0.150 |
Why?
|
| Atrial Function, Left | 1 | 2018 | 50 | 0.150 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2018 | 47 | 0.150 |
Why?
|
| Monocytes | 1 | 2019 | 218 | 0.150 |
Why?
|
| Myocardial Infarction | 3 | 2014 | 373 | 0.150 |
Why?
|
| Hydroxyethylrutoside | 1 | 2017 | 1 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 285 | 0.150 |
Why?
|
| Blood Circulation | 1 | 2017 | 30 | 0.150 |
Why?
|
| Heart Massage | 1 | 2017 | 12 | 0.150 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 93 | 0.140 |
Why?
|
| Allografts | 1 | 2018 | 181 | 0.140 |
Why?
|
| Renal Veins | 1 | 2017 | 28 | 0.140 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 178 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 39 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3443 | 0.140 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 192 | 0.140 |
Why?
|
| Macrophages | 1 | 2019 | 571 | 0.130 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 27 | 0.130 |
Why?
|
| Ultrasonography | 5 | 2009 | 711 | 0.130 |
Why?
|
| Health Status | 1 | 2018 | 370 | 0.130 |
Why?
|
| Upper Extremity | 1 | 2016 | 52 | 0.130 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 198 | 0.130 |
Why?
|
| Catheterization | 1 | 2017 | 237 | 0.130 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2015 | 11 | 0.130 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 97 | 0.130 |
Why?
|
| Coronary Aneurysm | 1 | 2015 | 16 | 0.130 |
Why?
|
| Incidence | 2 | 2017 | 1592 | 0.130 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 15 | 0.120 |
Why?
|
| Quality of Life | 1 | 2023 | 1662 | 0.120 |
Why?
|
| Aortic Valve | 1 | 2017 | 243 | 0.120 |
Why?
|
| Hemoptysis | 1 | 2014 | 24 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1591 | 0.120 |
Why?
|
| Contrast Media | 1 | 2019 | 1090 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 475 | 0.120 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2014 | 12 | 0.120 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 83 | 0.120 |
Why?
|
| Chicago | 2 | 2017 | 1423 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2019 | 779 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 685 | 0.120 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2015 | 89 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 188 | 0.110 |
Why?
|
| Urbanization | 1 | 2013 | 7 | 0.110 |
Why?
|
| Developed Countries | 1 | 2013 | 25 | 0.110 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1067 | 0.110 |
Why?
|
| Ventricular Dysfunction | 1 | 2013 | 28 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1855 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 2014 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 705 | 0.110 |
Why?
|
| Graft Rejection | 1 | 2019 | 1064 | 0.110 |
Why?
|
| North America | 1 | 2013 | 184 | 0.110 |
Why?
|
| Software | 1 | 2017 | 665 | 0.110 |
Why?
|
| Canada | 1 | 2013 | 208 | 0.110 |
Why?
|
| Patient Discharge | 1 | 2015 | 320 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2018 | 716 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 226 | 0.100 |
Why?
|
| Dyspnea | 2 | 2010 | 75 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 849 | 0.100 |
Why?
|
| Hypotension | 1 | 2012 | 71 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2013 | 260 | 0.100 |
Why?
|
| Adolescent | 3 | 2017 | 9237 | 0.100 |
Why?
|
| Adult | 7 | 2019 | 26507 | 0.100 |
Why?
|
| Heart Rate | 3 | 2008 | 493 | 0.100 |
Why?
|
| Systole | 2 | 2008 | 115 | 0.090 |
Why?
|
| Recurrence | 2 | 2011 | 1140 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 275 | 0.090 |
Why?
|
| Vascular Patency | 2 | 2020 | 126 | 0.090 |
Why?
|
| Acute Disease | 5 | 2009 | 841 | 0.090 |
Why?
|
| Respiratory System Agents | 1 | 2009 | 7 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 60 | 0.080 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2009 | 24 | 0.080 |
Why?
|
| Prevalence | 1 | 2013 | 1240 | 0.080 |
Why?
|
| Smoking | 1 | 2013 | 620 | 0.080 |
Why?
|
| Amyloid | 1 | 2009 | 94 | 0.080 |
Why?
|
| Cardiology | 1 | 2010 | 115 | 0.080 |
Why?
|
| Internationality | 1 | 2008 | 69 | 0.080 |
Why?
|
| Assisted Circulation | 1 | 2008 | 16 | 0.080 |
Why?
|
| Ventricular Function | 1 | 2008 | 53 | 0.080 |
Why?
|
| Diastole | 3 | 2018 | 141 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1400 | 0.080 |
Why?
|
| Prosthesis Design | 2 | 2019 | 296 | 0.080 |
Why?
|
| Pacemaker, Artificial | 1 | 2008 | 94 | 0.080 |
Why?
|
| Atrial Function | 1 | 2007 | 19 | 0.070 |
Why?
|
| Remission Induction | 1 | 2009 | 740 | 0.070 |
Why?
|
| Hypertension | 1 | 2013 | 741 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 36 | 0.070 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 60 | 0.070 |
Why?
|
| Critical Care | 1 | 2010 | 380 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 341 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 123 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1177 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2007 | 101 | 0.070 |
Why?
|
| Catheterization, Central Venous | 1 | 2007 | 115 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2008 | 463 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 966 | 0.070 |
Why?
|
| Physical Examination | 1 | 2007 | 148 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2010 | 570 | 0.070 |
Why?
|
| ROC Curve | 1 | 2008 | 781 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 111 | 0.060 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 352 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1940 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2006 | 335 | 0.050 |
Why?
|
| Program Development | 1 | 2023 | 123 | 0.050 |
Why?
|
| Life Style | 1 | 2023 | 172 | 0.050 |
Why?
|
| Length of Stay | 2 | 2019 | 732 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 865 | 0.050 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 25 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2007 | 1041 | 0.050 |
Why?
|
| Limb Salvage | 1 | 2020 | 35 | 0.050 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 29 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2020 | 82 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 147 | 0.040 |
Why?
|
| Algorithms | 3 | 2017 | 1875 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 270 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2019 | 46 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 122 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2020 | 274 | 0.040 |
Why?
|
| Bioprosthesis | 1 | 2019 | 39 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 319 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 94 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 142 | 0.040 |
Why?
|
| Endocardium | 1 | 2018 | 98 | 0.040 |
Why?
|
| Tricuspid Valve | 1 | 2018 | 97 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2019 | 466 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 16 | 0.040 |
Why?
|
| Phlebography | 1 | 2017 | 66 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 251 | 0.040 |
Why?
|
| Animals | 3 | 2020 | 27317 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 461 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 50 | 0.030 |
Why?
|
| Education, Medical | 1 | 2019 | 243 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 850 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 288 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 604 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2014 | 11 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 71 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 778 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1182 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 157 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 186 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 46 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 143 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 567 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 1149 | 0.030 |
Why?
|
| Furosemide | 1 | 2012 | 34 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1533 | 0.030 |
Why?
|
| Diuretics | 1 | 2012 | 75 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 3147 | 0.020 |
Why?
|
| Sodium | 1 | 2012 | 331 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 682 | 0.020 |
Why?
|
| Edema, Cardiac | 1 | 2010 | 3 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2010 | 38 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 783 | 0.020 |
Why?
|
| Dizziness | 1 | 2010 | 26 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2010 | 34 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 103 | 0.020 |
Why?
|
| Pulmonary Atelectasis | 1 | 2009 | 18 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 321 | 0.020 |
Why?
|
| Dobutamine | 1 | 2009 | 61 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 266 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 3373 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 449 | 0.020 |
Why?
|
| Heart, Artificial | 1 | 2008 | 9 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 63 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 434 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2007 | 36 | 0.020 |
Why?
|
| Positive-Pressure Respiration | 1 | 2007 | 41 | 0.020 |
Why?
|
| Jugular Veins | 1 | 2007 | 74 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 85 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2007 | 156 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 198 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 684 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2007 | 102 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 894 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 11737 | 0.020 |
Why?
|
| Observer Variation | 1 | 2007 | 610 | 0.020 |
Why?
|
| Organ Size | 1 | 2006 | 369 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 1212 | 0.020 |
Why?
|
| Patient Selection | 1 | 2008 | 682 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 779 | 0.010 |
Why?
|